Important

Research Use Notice

All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.

Product Documentation

Details, specifications, and reviews

Description

AOD-9604 + CJC-1295 + Ipamorelin 12 mg blend

Buy AOD/CJC/Ipamorelin blend with 12 mg total labeled material: 6 mg AOD-9604, 3 mg CJC-1295 and 3 mg Ipamorelin. This research blend is supplied as lyophilized powder in one boxed 3 mL vial.

  • AOD-9604: 6 mg per vial
  • CJC-1295 DAC: 3 mg per vial
  • Ipamorelin: 3 mg per vial
  • Total blend: 12 mg per vial

Compare the formulation before choosing

The 2:1:1 proportions are by mass, not by number of molecules. AOD-9604 contributes half the labeled total. This differs from the CJC-1295 NO DAC + Ipamorelin 10 mg blend, which contains no AOD-9604 and has 5 mg of each listed ingredient.

The CJC component in this three-peptide blend is CJC-1295 with DAC, reference CAS 446262-90-4. DAC is the albumin-reactive modification. This distinguishes the formulation from the separately listed NO DAC + Ipamorelin blend.

Separate AOD-9604 5 mg and Ipamorelin 5 mg listings provide alternatives when components need to be selected independently.

Research on the individual components

Heffernan and colleagues compared AOD9604 with full-length growth hormone in mice and receptor assays. The fragment did not compete for the hGH receptor in the reported assay. It should not be described as interchangeable with full-length hGH.

CJC development research examined albumin-conjugated GRF analogs, whereas Raun and colleagues characterized Ipamorelin’s growth-hormone-release responses in pituitary-cell and animal models. These papers studied defined individual materials, not this 6:3:3 mg mixture. They do not establish a combined effect or the blend’s stability.

Product records and handling

Open Documents for the available product files. Confirm each component’s identity, the labeled formulation and any component-specific analytical results needed for the intended experiment. A total powder measurement alone cannot establish all three peptide amounts.

Storage and handling requirements must apply to the complete mixture. The 3 mL specification is container capacity, not liquid supplied or an instruction for preparing the material. Any certificate of analysis used in the evaluation should match the actual product and lot.

Need Assistance?

Questions about product documentation?

Our support team can assist with product records, lot information, order questions, and certificate verification.

Contact Support